Li Ya-Jun, Yi Ping-Yong, Li Ji-Wei, Liu Xian-Ling, Tang Tian, Zhang Pei-Ying, Jiang Wen-Qi
Department of Lymphoma and Hematology, Hunan Cancer Hospital, 283 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, P. R. China.
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, P. R. China.
Chin J Cancer. 2017 Jul 31;36(1):62. doi: 10.1186/s40880-017-0229-0.
The prognostic significance of ABO blood type for lymphoma is largely unknown. We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL).
We retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers. The prognostic value of ABO blood type was evaluated using Kaplan-Meier curves and Cox proportional hazard models. The prognostic values of the International Prognostic Index (IPI) and the Korean Prognostic Index (KPI) were also evaluated.
Compared with patients with blood type O, those with blood type non-O tended to display elevated baseline serum C-reactive protein levels (P = 0.038), lower rate of complete remission (P = 0.005), shorter progression-free survival (PFS, P < 0.001), and shorter overall survival (OS, P = 0.001). Patients with blood type O/AB had longer PFS (P < 0.001) and OS (P = 0.001) compared with those with blood type A/B. Multivariate analysis demonstrated that age >60 years (P < 0.001), mass ≥5 cm (P = 0.001), stage III/IV (P < 0.001), elevated serum lactate dehydrogenase (LDH) levels (P = 0.001), and blood type non-O were independent adverse predictors of OS (P = 0.001). ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low- and high-to-intermediate-risk groups.
ABO blood type was an independent predictor of clinical outcome for patients with ENKTL.
ABO血型对淋巴瘤的预后意义尚不清楚。我们评估了ABO血型在结外自然杀伤（NK）/T细胞淋巴瘤（ENKTL）患者中的预后作用。
我们回顾性分析了来自三个癌症中心的697例新诊断ENKTL患者的临床资料。使用Kaplan-Meier曲线和Cox比例风险模型评估ABO血型的预后价值。还评估了国际预后指数（IPI）和韩国预后指数（KPI）的预后价值。
与O型血患者相比，非O型血患者倾向于表现出更高的基线血清C反应蛋白水平（P = 0.038）、更低的完全缓解率（P = 0.005）、更短的无进展生存期（PFS，P < 0.001）和更短的总生存期（OS，P = 0.001）。与A型/ B型血患者相比，O型/ AB型血患者的PFS（P < 0.001）和OS（P = 0.001）更长。多变量分析表明，年龄> 60岁（P < 0.001）、肿块≥5 cm（P = 0.001）、III/IV期（P < 0.001）、血清乳酸脱氢酶（LDH）水平升高（P = 0.001）和非O型血是OS的独立不良预测因素（P = 0.001）。发现ABO血型在区分IPI低风险组中不同预后的患者方面优于IPI，在区分中低风险组和高至中风险组方面优于KPI。
ABO血型是ENKTL患者临床结局的独立预测因素。
